Bedfont Scientific Limited articles

National No Smoking Day is observed in the UK annually on the second Wednesday of March, falling on the 12th of March 2025. Inaugurated on Ash Wednesday in 1984, the day aims to raise awareness of the dangers of smoking and encourage smokers to quit, highlighting the benefits of a smoke-free life.

Smoking poses serious health risks, affecting nearly every organ in the body. Smokers significantly increase the risk of developing Chronic Obstructive Pulmonary Disease (COPD) and lung cance

Bedfont^® Scientific Limited is an experienced med-tech company with over 48 years of expertise in designing and manufacturing medical breath analysis devices. Bedfont^® works with a Medical Advisory Board, made up of key opinion leaders (KOLs) who are experts in their respective fields. The Medical Advisory Board plays a crucial role in the development of the products and services, ensuring the unique needs of clients are met.

This case study has been

Hydrogen and methane breath testing (HMBT) is a non-invasive diagnostic tool frequently used to assess small intestinal bacterial overgrowth (SIBO) and carbohydrate malabsorption disorders such as lactose and fructose intolerance. Despite its widespread use in adults, its application in children is less standardised, and clinicians often face uncertainties about adapting adult protocols for the paediatric population.

This article discusses the use of HMBT in children, highlights the ke

In November 2024, the British Thoracic Society (BTS), Scottish Intercollegiate Guidelines Network (SIGN), and the National Institute of Care Excellence (NICE) asthma guidelines1 were released superseding the previously separate guidelines from BTS/SIGN2 and NICE3. The new joint guideline, based on current clinical evidence and cost-effective modelling, clears up the previous uncertainty about the diagnosis and routine management of asthma. This resource will help understand where Fr

On Wednesday, 27th November, the National Institute for Health and Care Excellence (NICE), the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN) updated and published a joint guideline on asthma diagnosis, monitoring, and chronic asthma management. 

Streamlining asthma management

BTS/SIGN and NICE published guidelines independent of each other. To align approaches to asthma care throughout the UK, NICE has undertaken

Stoptober takes place every October in the UK. Launched in 2012, the campaign encourages smokers to quit for 28 days. The theme for 2024 is ‘When you stop smoking, good things start to happen’. Bedfont^® Scientific Ltd., world leaders in breath analysis, hosted a discussion with Smokerlyzer^® Medical Advisory Board Members Dr Amer Siddiq Amer Nordin and Dr Anne Yee. The panel explored the impact Stoptober has on people’s quit smoking attempts

Bedfont^® Scientific Limited hosted an informative webinar Children with Asthma, with seasoned respiratory nurse Carol Stonham MBE leading the discussion along with Kirsty at Medway Asthma Self-Help (MASH). The webinar was a private screening for local Medway football coaches and gave valuable insights on managing, treating and recognising an asthma emergency.

Carol Stonham MBE, has been a registered nurse since 1986, transitioning from acute hospital settings to primary

Bedfont^® Scientific Limited hosted an insightful webinar Mastering Gut Health: Understanding SIBO, Carbohydrate Malabsorption, and Accurate Gastrointestinal Investigation. Gastrointestinal Physiologist and Bedfont^® Medical Advisory Board member Melissa Dooley, led the discussion and shared valuable information on various gastrointestinal disorders and the importance of not self-diagnosing.

Melissa Dooley began her career as a Gastrointestinal Physiologist

Methods of measuring FeNO
Fractional exhaled nitric oxide (FeNO) measurement plays a crucial role in the diagnosis and management of airway inflammation. FeNO testing is recommended by the National Institute for Health and Care Excellence (NICE) to help diagnose asthma¹, with the NObreath^® device one of three devices recommended by NICE¹.

In 2005 the American Thoracic Society (ATS) and the European Respiratory Society (ERS) pub

FeNO Testing in Asthma Care

Although airway eosinophilic inflammation is a key characteristic of asthma, there are few methods available to measure it. This inflammation can be assessed by measuring eosinophils and eosinophilic cationic protein (ECP) in sputum or by measuring ECP in blood samples1. However, these methods are considered time-consuming, expensive, and not readily available.

For most asthma patients, airway inflammation is driven by an allergen-ind